This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): PC-DAC:Exendin-4
Description: DAC:GLP-1 is a long-acting formulation of exenatide, conjugated to recombinant human albumin via ConjuChem's Preformed Conjugate-Drug Affinity Complex (PC-DAC) technology. DAC:GLP-1 is given via injection; a 31 gauge needle can be used.
Exenatide is a peptide that exhibits multiple anti-diabetic actions of the mammalian hormone glucagon-like peptide (GLP-1). GLP-1 is an incretin hormone secreted in the small intestine and colon in response to food intake. It enhances insulin secretion when glucose levels are high, suppresses inappropriate glucagons secretion (glucagon has the opposite effect of insulin), slows gastric emptying (slowing entry of ingested nutrients into the bloodstream, hence limiting post-prandial glucose), and via actions on the brain is thought to promote satiety.
Additional information available to subscribers only: